How many studies have been conducted on Lymphotoxin Alpha?

BiohacksAI has indexed 300 PubMed studies on Lymphotoxin Alpha, including 3 randomized controlled trials (RCTs). 39% of studies involve human subjects.

What are the main research areas for Lymphotoxin Alpha?

The primary research domains for Lymphotoxin Alpha are 🔬 Oncology, 🔬 Inflammation, 🛡️ Immunity. This is based on analysis of 300 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Lymphotoxin Alpha

A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR.

300+ PubMed studies analyzed · 3 RCTs · Evidence Score: 49.5

Research Domains

Lymphotoxin Alpha has been studied across 17 research domains including 🔬 Oncology, 🔬 Inflammation, 🛡️ Immunity, ❤️ Cardiovascular, 🦴 Bone & Joint. The primary research focus is 🔬 Oncology with 59% of studies addressing this area.

Loading evidence profile...

This evidence profile for Lymphotoxin Alpha is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.